StreetAlpha.app
Home › Stocks › MRVI

Maravai Lifesciences Holdings, Inc. (MRVI)

Healthcare
$7.28
▼ −1.62%
LAST CLOSE · NOV 17

Maravai LifeSciences makes nucleic acid products and bioprocess testing kits and services for drug developers and researchers. It last closed at $7.28 on Nov 17, down 1.62% on the day. The average 12-month price target from 2 analysts is $9.50 (+30.5% from the last close), with a high of $11.00 and a low of $8.00. In the past 30 days there were 2 dark pool prints totaling $578K, the largest $299K.

AI Auto Pilots
Is MRVI in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$213.0M
+10.7% vs a year ago
Net income
−$65.7M
−30.8% margin
EPS (diluted)
−$0.44
Free cash flow
−$13.3M
−6.2% margin
Balance sheet
Cash & equivalents
$73.0M
At Sep 30
Debt
$147.2M
At Sep 30
Shareholder equity
$195.9M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $799.2M$799.2MFY2021FY2022: $883.0M$883.0MFY2022FY2023: $288.9M$288.9MFY2023FY2024: $259.2M$259.2MFY2024FY2025: $185.7M$185.7MFY2025

From MRVI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy · 1 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy · 1 Hold
2firms
1 Buy1 Hold0 Sell
Only 2 firms rated MRVI in the past 90 days, not enough for a consensus
Average 12-month target
$9.50
▲ 30.5% upside

Based on 2 analysts who set a price target on MRVI in the past 90 days. The average target is $9.50, with a high of $11.00 and a low of $8.00, compared with the last close of $7.28.

Low $8.00Avg $9.50High $11.00
Blue marker: last close $7.28
Highest target$11.00
Average target$9.50
Lowest target$8.00
Latest rating changes
KeybancUpgrade
Nov 12Buy$11
UBSMaintained
Sep 9Hold$8
Wells FargoMaintained
Aug 7Buy$6.50
DateFirmActionRatingPrice target
Nov 12KeybancUpgradeBuy$11
Sep 9UBSMaintainedHold$8
Aug 7Wells FargoMaintainedBuy$6.50
Loading…

Technical Analysis

MRVI · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 5% below its 20 day and 2% below its 50 day average. It is 25% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 47). The nearest support is the Pivot S1 at $7.14, and the nearest resistance the Pivot at $7.31.

Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 6.9%/day
Key levels
$9.4252 week high+29.4%
$7.6520 day average+5.1%
$7.44Pivot R1+2.2%
$7.44Swing high (Jul 23)+2.2%
$7.4050 day average+1.6%
$7.31Pivot+0.4%
$7.28Last close
$7.14Pivot S1−1.9%
$7.10100 day average−2.5%
$6.80Swing low (Nov 5)−6.6%
$5.47200 day average−24.9%
$2.8052 week low−61.5%
Indicators
RSI (14)46.74Middle of its rangeNeutral
MACD0.02Below its signal lineBearish
Stochastic33.3Middle of its rangeNeutral
ADX (14)10.6No clear trend
Williams %R-73.6Oversold below −80, overbought above −20Neutral
CCI (20)-71.9Oversold below −100, overbought above 100Neutral
Rate of change−2.3%Change over 10 sessionsBearish
ATR (14)$0.50Typical daily range, 6.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for MRVI

What happened before

See how MRVI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow MRVI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How MRVI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in MRVI in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$578K
Largest print
$299K
Loading…

MRVI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲122 buying vs 82 selling
  • ●Shares held by funds +1.0%
  • ▲Funds holding +23
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding203180+12.8%
In funds' top 1024−50.0%
Held by funds–––
New / increased52 / 7046 / 57+18.4%
Reduced / sold out53 / 2951 / 23+10.8%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MRVI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MRVI is in one of them and how their past MRVI trades turned out.

MRVI in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MRVI in an article yet. Here's the latest on the wider market.

MRVI Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed May 19
Who traded MRVI · since 2023
Latest 1 filing
$1K – $15KTraded Apr 10, 2023Filed May 19, 2023
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KApr 10, 2023May 19, 202339 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Maravai Lifesciences Holdings

Maravai LifeSciences is a life sciences company based in San Diego, California. Its TriLink segment makes modified nucleic acids for customers' research, therapeutic and vaccine programs, and sells research products for labeling and detecting proteins in cells and tissue samples. Its Cygnus segment sells kits and products for testing biologic drug manufacturing, including host cell protein and impurity detection and viral clearance prediction, and offers services such as custom antibody development and mass spectrometry. Its customers include drug developers, vaccine makers, researchers and biologic drug manufacturers.

Headquarters
San Diego, CA